Publication details

Úskalí dávkování azathioprinu a cyklosporinu v terapii myastenie

Title in English Challenges of ciciosporin and azathioprin dosage for myasthemia gravis
Authors

HORÁKOVÁ Magda VOHÁŇKA Stanislav

Year of publication 2017
Type Article in Periodical
Magazine / Source Neurologie pro praxi
MU Faculty or unit

Faculty of Medicine

Citation
Field Neurology, neurosurgery, neurosciences
Keywords azathioprin; ciciosporin; cyclosporin; neoral; therapeutic drug monitoring
Description Azathioprin (Imuran) and ciciosporin (Sandimmun Neoral, Equoral) are among the most widely used immunosuppressive drugs for myasthenia gravis. They are very efficient and help to improve patient's quality of life. However, such therapy has some risks. At least part of the risks can be avoided by managing the right dose, which requires certain experience. The aim of this article is a review of their side effects, metabolic pathways and interactions, therapeutic drug monitoring and some dosage recommendations.

You are running an old browser version. We recommend updating your browser to its latest version.

More info